Pharmaceutical firm Acusphere has received $15 million in a round of private equity financing led by Thomas Weisel Capital Partners. Watertown, MA-based Acusphere said it would use the financing to support ongoing clinical development of its three product candidates, including its AI-700 ultrasound contrast agent for the detection of coronary artery disease.
By AuntMinnie.com staff writersJuly 24, 2002
Related Reading
Acusphere US contrast agent research presented at ASE, July 19, 2001
Copyright © 2002 AuntMinnie.com